Martina Zucchetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martina Zucchetti has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Dello Russo
Arrhythmology Clinic Department, Azienda Ospedaliera Universitaria delle Marche , Ancona
10 shared publications Claudio Tondo
Centro Cardiologico Monzino IRCCS
10 shared publications- Michela Casella
Department of Clinical, Special, and Dental Sciences, Marche Polytechnic University , Ancona
10 shared publications Andrea Natale
Texas Cardiac Arrhythmia Institute at St David’s Medical Center
8 shared publications- Corrado Carbucicchio
Department of Clinical Electrophysiology & Cardiac Pacing, Centro Cardiologico Monzino IRCCS , Milan
8 shared publications Pasquale Santangeli
Texas Cardiac Arrhythmia Institute at St David’s Medical Center
7 shared publications
Latest Publications
- 16 March 2014
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 40 (1) , 23-31
Simultaneous assessment of contact pressure and local electrical coupling index using robotic navigation
Contact with cardiac tissue is a determinant of lesion efficacy during atrial fibrillation (AF) ablation. The Sensei®X Robotic Catheter System (Hansen Medical, CA) has been validated for contact force sensing. The electrical coupling index (ECI) from the EnSite Contact™ system (St. Jude Medical, MN) has been validated as an indicator of tissue contact. We aimed at analyzing ECI behavior during radiofrequency (RF) pulses maintaining a stable contact through the robotic navigation contact system. In 15 patients (age, 59 ± 12) undergoing AF ablation, pulmonary vein (PV) isolation was guided by the Sensei®X System, employing the Contact™ catheter. During the procedure, we assessed ECI changes associated with adequate contact based on the IntelliSense® force-sensing technology (Hansen Medical, CA. Baseline contact (27 ± 8 g/cm2) ECI value was 99 ± 13, whereas ECI values in a noncontact site (0 g/cm2) and in a light contact site (1–10 g/cm2) were respectively 66 ± 12 and 77 ± 10 (p < 0.0001). Baseline contact ECI values were not different depending on AF presentation (paroxysmal AF, 98 ± 9; persistent AF, 100 ± 9) or on cardiac rhythm (sinus rhythm, 97 ± 7; AF,101 ± 10). In all PVs, ECI was significantly reduced during and after ablation (ECI during RF, 56 ± 15; ECI after RF, 72 ± 16; p < 0.001). A mean reduction of 32.2 % during RF delivery and 25.4 % immediately after RF discontinuation compared with baseline ECI was observed. Successful PV isolation is associated with a significant decrease in ECI of at least 20 %. This may be used as a surrogate marker of effective lesion in AF ablation.
- 16 March 2014
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 40 (1) , 23-31
Simultaneous assessment of contact pressure and local electrical coupling index using robotic navigation
Contact with cardiac tissue is a determinant of lesion efficacy during atrial fibrillation (AF) ablation. The Sensei®X Robotic Catheter System (Hansen Medical, CA) has been validated for contact force sensing. The electrical coupling index (ECI) from the EnSite Contact™ system (St. Jude Medical, MN) has been validated as an indicator of tissue contact. We aimed at analyzing ECI behavior during radiofrequency (RF) pulses maintaining a stable contact through the robotic navigation contact system. In 15 patients (age, 59 ± 12) undergoing AF ablation, pulmonary vein (PV) isolation was guided by the Sensei®X System, employing the Contact™ catheter. During the procedure, we assessed ECI changes associated with adequate contact based on the IntelliSense® force-sensing technology (Hansen Medical, CA. Baseline contact (27 ± 8 g/cm2) ECI value was 99 ± 13, whereas ECI values in a noncontact site (0 g/cm2) and in a light contact site (1–10 g/cm2) were respectively 66 ± 12 and 77 ± 10 (p < 0.0001). Baseline contact ECI values were not different depending on AF presentation (paroxysmal AF, 98 ± 9; persistent AF, 100 ± 9) or on cardiac rhythm (sinus rhythm, 97 ± 7; AF,101 ± 10). In all PVs, ECI was significantly reduced during and after ablation (ECI during RF, 56 ± 15; ECI after RF, 72 ± 16; p < 0.001). A mean reduction of 32.2 % during RF delivery and 25.4 % immediately after RF discontinuation compared with baseline ECI was observed. Successful PV isolation is associated with a significant decrease in ECI of at least 20 %. This may be used as a surrogate marker of effective lesion in AF ablation.
- 1 December 2013
- Published by Elsevier in Heart Rhythm
- Vol. 10 (12) , 1850-1858
High-density substrate-guided ventricular tachycardia ablation: Role of activation mapping in an attempt to improve procedural effectiveness
- 1 December 2013
- Published by Elsevier in Heart Rhythm
- Vol. 10 (12) , 1850-1858
High-density substrate-guided ventricular tachycardia ablation: Role of activation mapping in an attempt to improve procedural effectiveness
- 6 April 2013
- Published by Cardiofront, LLC
- Vol. 5 (6) , 786
Role of Intracardiac echocardiography in Atrial Fibrillation Ablation.
In the recent years, several new evidences support catheter-based ablation as a treatment modality of atrial fibrillation (AF). Based on a plenty of different applications, intracardiac echocardiography (ICE) is now a well-established technology in complex electrophysiological procedures, in particular in AF ablation. ICE contributes to improve the efficacy and safety of such procedures defining the anatomical structures involved in ablation procedures and monitoring in real time possible complications. In particular ICE allows: a correct identification of the endocardial structures; a guidance of transseptal puncture; an assessment of accurate placement of the circular mapping catheter; an indirect evaluation of evolving lesions during radiofrequency (RF) energy delivery via visualization of micro and macrobubbles tissue heating; assessment of catheter contact with cardiac tissues. Recently, also the feasibility of the integration of electroanatomical mapping (EAM) and intracardiac echocardiography has been demonstrated, combining accurate real time anatomical information with electroanatomical data. As a matter of fact, different techniques and ablation strategies have been developed throughout the years. In the setting of balloon-based ablation systems, recently adopted by an increasing number of centers, ICE might have a role in the choice of appropriate balloon size and to confirm accurate occlusion of pulmonary veins. Furthermore, in the era of minimally fluoroscopic ablation, ICE has successfully provided a contribute in reducing fluoroscopy time. The purpose of this review is to summarize the current applications of ICE in catheter based ablation strategies of atrial fibrillation, focusing-on electronically phased-array ICE.
- 6 April 2013
- Published by Cardiofront, LLC
- Vol. 5 (6) , 786
Role of Intracardiac echocardiography in Atrial Fibrillation Ablation.
In the recent years, several new evidences support catheter-based ablation as a treatment modality of atrial fibrillation (AF). Based on a plenty of different applications, intracardiac echocardiography (ICE) is now a well-established technology in complex electrophysiological procedures, in particular in AF ablation. ICE contributes to improve the efficacy and safety of such procedures defining the anatomical structures involved in ablation procedures and monitoring in real time possible complications. In particular ICE allows: a correct identification of the endocardial structures; a guidance of transseptal puncture; an assessment of accurate placement of the circular mapping catheter; an indirect evaluation of evolving lesions during radiofrequency (RF) energy delivery via visualization of micro and macrobubbles tissue heating; assessment of catheter contact with cardiac tissues. Recently, also the feasibility of the integration of electroanatomical mapping (EAM) and intracardiac echocardiography has been demonstrated, combining accurate real time anatomical information with electroanatomical data. As a matter of fact, different techniques and ablation strategies have been developed throughout the years. In the setting of balloon-based ablation systems, recently adopted by an increasing number of centers, ICE might have a role in the choice of appropriate balloon size and to confirm accurate occlusion of pulmonary veins. Furthermore, in the era of minimally fluoroscopic ablation, ICE has successfully provided a contribute in reducing fluoroscopy time. The purpose of this review is to summarize the current applications of ICE in catheter based ablation strategies of atrial fibrillation, focusing-on electronically phased-array ICE.
- 1 August 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (8) , 1200-1206
Fragmented and delayed electrograms within fibrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: Results from a prospective risk stratification study
- 1 August 2012
- Published by Elsevier in Heart Rhythm
- Vol. 9 (8) , 1200-1206
Fragmented and delayed electrograms within fibrofatty scar predict arrhythmic events in arrhythmogenic right ventricular cardiomyopathy: Results from a prospective risk stratification study
- 1 June 2012
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 5 (3) , 492-498
Drug-Refractory Ventricular Tachycardias After Myocarditis
Background—Ventricular tachycardia (VT) is a significant therapeutic challenge in patients with myocarditis. This study aimed to assess the efficacy and safety of radiofrequency catheter ablation (RFCA) of VT in patients with myocarditis. Methods and Results—We enrolled 20 patients (15 men; age, 42 [28–52] years) with a history of biopsy-proven viral myocarditis and drug-refractory VT; 5 patients presented with electrical storm. The median left ventricular ejection fraction was 55% (45–60%). All patients underwent endocardial RFCA with an irrigated catheter, using contact electroanatomic mapping. Recurrence of sustained VT after endocardial RFCA was treated with additional epicardial RFCA. Endocardial RFCA was acutely successful in 14 patients (70%) while in the remaining 6 (30%) clinical VT was successfully ablated by epicardial RFCA. In 1 patient, hemodynamic instability required an intra-aortic balloon pump to complete RFCA. No major complication occurred during or after RFCA. Over a median follow-up time of 28 (11–48) months, 18 patients (90%) remained free of sustained VT; 2 patients (10%, both with baseline left ventricular ejection fraction ≤35%) died of acute heart failure unrelated to ventricular arrhythmias. Conclusions—In patients with myocarditis, RFCA of drug-refractory VT is feasible, safe, and effective. Epicardial RFCA should be considered as an important therapeutic option to increase success rate.
- 1 June 2012
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 5 (3) , 492-498
Drug-Refractory Ventricular Tachycardias After Myocarditis
Background—Ventricular tachycardia (VT) is a significant therapeutic challenge in patients with myocarditis. This study aimed to assess the efficacy and safety of radiofrequency catheter ablation (RFCA) of VT in patients with myocarditis. Methods and Results—We enrolled 20 patients (15 men; age, 42 [28–52] years) with a history of biopsy-proven viral myocarditis and drug-refractory VT; 5 patients presented with electrical storm. The median left ventricular ejection fraction was 55% (45–60%). All patients underwent endocardial RFCA with an irrigated catheter, using contact electroanatomic mapping. Recurrence of sustained VT after endocardial RFCA was treated with additional epicardial RFCA. Endocardial RFCA was acutely successful in 14 patients (70%) while in the remaining 6 (30%) clinical VT was successfully ablated by epicardial RFCA. In 1 patient, hemodynamic instability required an intra-aortic balloon pump to complete RFCA. No major complication occurred during or after RFCA. Over a median follow-up time of 28 (11–48) months, 18 patients (90%) remained free of sustained VT; 2 patients (10%, both with baseline left ventricular ejection fraction ≤35%) died of acute heart failure unrelated to ventricular arrhythmias. Conclusions—In patients with myocarditis, RFCA of drug-refractory VT is feasible, safe, and effective. Epicardial RFCA should be considered as an important therapeutic option to increase success rate.
- 1 January 2010
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 6 (3)
Atrial Fibrillation Ablation – New Approaches, New Technologies
Catheter ablation is now considered a first-line therapy for patients with symptomatic, drug-refractory atrial fibrillation (AF), but the need for great technical skills and incomplete insight into underlying mechanisms make the accomplishment of long-term favourable outcomes difficult to achieve. Technological innovation is aimed at making AF ablation a more effective practice that is no longer restricted to a few operators. The main fields of ongoing research include more reliable imaging modalities, more effective and faster ablation catheters (multielectrode and balloon catheters, catheters using alternative energy sources), force-sensing technology, remote navigation systems and algorithms implemented in the mapping systems in order to characterise the atrial substrate. Attention is also given to improving the safety profile of AF ablation procedures. Finally, novel devices for stroke prophylaxis and post-ablation follow-up have been introduced into clinical practice. Nevertheless, AF ablation remains a technically challenging procedure, and the extent to which much the new technologies and tools will be able to eventually improve outcomes and expand the current indications is still unclear.
- 1 January 2010
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 6 (3)
Atrial Fibrillation Ablation – New Approaches, New Technologies
Catheter ablation is now considered a first-line therapy for patients with symptomatic, drug-refractory atrial fibrillation (AF), but the need for great technical skills and incomplete insight into underlying mechanisms make the accomplishment of long-term favourable outcomes difficult to achieve. Technological innovation is aimed at making AF ablation a more effective practice that is no longer restricted to a few operators. The main fields of ongoing research include more reliable imaging modalities, more effective and faster ablation catheters (multielectrode and balloon catheters, catheters using alternative energy sources), force-sensing technology, remote navigation systems and algorithms implemented in the mapping systems in order to characterise the atrial substrate. Attention is also given to improving the safety profile of AF ablation procedures. Finally, novel devices for stroke prophylaxis and post-ablation follow-up have been introduced into clinical practice. Nevertheless, AF ablation remains a technically challenging procedure, and the extent to which much the new technologies and tools will be able to eventually improve outcomes and expand the current indications is still unclear.
- Published by Cardiofront, LLC
(undefined)